Dr. Relling has been a pioneer in both the science and clinical application of pharmacogenomics. Her research has resulted in seminal laboratory discoveries that unraveled the mechanisms of drug-induced adverse effects, and the integration of biologic, genomic, and pharmacologic discoveries into comprehensive clinical protocols, leading to improved cure rates for children with acute lymphoblastic leukemia. In recognition for her work she was elected to the Institute of Medicine (now National Academies of Medicine) in 2009 and received the Pediatric Oncology Award from ASCO. Mary has been recognized by the American Society for Clinical Pharmacology and Therapeutics. Mary, along with Dr. Teri Klein of Stanford, co-led the formation of the Clinical Pharmacogenomics Implementation Consortium (CPIC) that has published pharmacogenetic guidelines for thirty-five drugs. These guidelines are now implemented around the globe. Mary received her Bachelor of Science degree from the University of Arizona and her PharmD from the University of Utah College of Pharmacy.
Track 1, January 27
Mary Relling, St. Jude
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.